At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.
Search results for: biosimilars
Neti Pots, Nurse Ambassadors & American Healthcare
Just YouTube it. As a rheumatologist who sees many patients with granulomatosis with polyangiitis (GPA), I have spent a significant portion of my life talking to people about neti pots. Originally, the neti pot was part of the Ayurvedic tradition. Neti pots were used to flush the sinuses with water, milk and ghee, or to…
FDA Provides 2020 Rheumatology Drug Update
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
Biologics in Rheumatology: Revolution & Perspectives
A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.
Patients Demonstrated Good Medication Adherence While Taking Biosimilar Treatment
Researchers found half of patients taking the biosimilar infliximab-dyyb (Inflectra) remained highly adherent to medication use after 12 months.
The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?
ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…
Advancing Rheumatology Care Through State & Local Societies
As his term as chair of the Affiliate Society Council draws to a close, Chris Adams, MD, FACP, FACR, reflects on the personal and professional rewards of volunteer leadership and the importance and impact of coordinated state-level advocacy efforts for the future of rheumatology.
Pharmacists Not Required to Substitute Generics for Brand-Name Drugs in Most U.S. States
(Reuters Health)—Only 19 U.S. states mandate that pharmacists fill prescriptions for brand-name small molecule drugs with generics when available, with the 31 remaining states allowing but not requiring these substitutions, a new study finds. Researchers examined laws on the books as of September 2019 pertaining to generic substitution of small molecule drugs, as well as…
Biosimilar Prescribing Habits in the VA & Academic Settings
In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 32
- Next Page »